ATHX

Athersys Stock Price

1.64
0.00 (0.0%)
1.64

Low
1.53

52 Week Range

High
3.39

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Athersys Inc ATHX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.64 07:00:00
Open Price Low Price High Price Close Price Prev Close
1.64
Bid Price Ask Price Spread News
1.62 1.69 0.07 - -
Trades Volume Avg Volume 52 Week Range
1 1 2,635,578 1.53 - 3.39
Last Trade Time Type Quantity Stock Price Currency
04:20:17 1 $ 1.65 USD

Athersys Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 324.23M 197.70M 178.39M $ 5.63M $ - -0.29 -5.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Athersys News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATHX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.721.771.581.672,251,854-0.08-4.65%
1 Month1.781.981.561.742,589,355-0.14-7.87%
3 Months2.033.031.562.143,234,300-0.39-19.21%
6 Months1.653.031.532.022,712,112-0.01-0.61%
1 Year2.223.391.532.312,971,362-0.58-26.13%
3 Years2.054.421.002.211,663,446-0.41-20.0%
5 Years2.344.421.002.111,288,086-0.70-29.91%

Athersys Description

Athersys Inc is a clinical-stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.


Your Recent History
NASDAQ
ATHX
Athersys
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.